Get the Stockscreener App
5.53
0.00%
0.00
Abeona Therapeutics Inc stock is traded at $5.53, with a volume of 956.36K.
It is up +0.00% in the last 24 hours and down -2.64% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$5.53
Open:
$5.53
24h Volume:
956.36K
Relative Volume:
0.82
Market Cap:
$315.18M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
5.5455
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
+1.28%
1M Performance:
-2.64%
6M Performance:
+3.17%
1Y Performance:
-11.45%
1-Day Range:
$5.505
$5.695
1-Week Range:
$5.24
$5.695
52-Week Range:
$4.00
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.53 | 315.18M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics (ABEO) investors approve equity plan boost, keep director notice rule - Stock Titan
ABEO: All proposals passed except the advance notice provision amendment for director nominations - TradingView
Abeona Therapeutics Inc. Announces Resignation of Michael Amoroso as Member of Board of Directors, Nominating and Corporate Governance Committee, Effective June 11, 2026 - marketscreener.com
Michael Amoroso resigns from Abeona board and nominating committee - TradingView
Abeona (NASDAQ: ABEO) director Michael Amoroso steps down from board - Stock Titan
Updated Abeona Therapeutics (NASDAQ: ABEO) investor presentation furnished in 8-K filing - Stock Titan
Abeona Therapeutics CFO Joseph Vazzano sells $265,242 in stock By Investing.com - Investing.com Nigeria
Abeona Therapeutics CCO Vasanthavada Madhav sells $51,548 in shares. - Investing.com UK
Abeona Therapeutics CEO sells $301,920 in stock By Investing.com - Investing.com South Africa
Abeona Therapeutics CCO Vasanthavada Madhav sells $51,548 in shares. By Investing.com - Investing.com Nigeria
Abeona Therapeutics SVP, chief legal officer sells $59,645 in stock - Investing.com UK
Abeona Therapeutics SVP, chief legal officer sells $59,645 in stock By Investing.com - Investing.com Nigeria
Abeona Therapeutics CFO Joseph Vazzano sells $265,242 in stock - Investing.com
Abeona Therapeutics CEO sells $301,920 in stock - Investing.com
[Form 4] ABEONA THERAPEUTICS INC. Insider Trading Activity - Stock Titan
(ABEO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ABEO (NASDAQ: ABEO) insider sales: 13,421 shares reported, plus 785-share sale - Stock Titan
ABEO (NASDAQ: ABEO) notice: proposed resale of 10,000 shares via Stifel - Stock Titan
[144] ABEONA THERAPEUTICS INC. SEC Filing - Stock Titan
ABEO (NASDAQ: ABEO) files Form 144 to sell 112,276 compensation shares - Stock Titan
Proposed resale notice — ABEO (Nasdaq: ABEO) lists 25,000 shares - Stock Titan
Abeona Advances ABO-701 T-Cell Therapy Toward IND - The Globe and Mail
Abeona Therapeutics reports constructive Pre-IND meeting with FDA on ABO-701, IND targeted for 2027 - TradingView
Abeona Therapeutics (ABEO) details FDA Pre-IND meeting and 2027 IND goal for ABO-701 - Stock Titan
ABEO Should I Buy - Intellectia AI
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Price-Driven Insight from (ABEO) for Rule-Based Strategy - Stock Traders Daily
ABEO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics (ABEO) director reports bona fide 500-share gift - Stock Titan
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - The Manila Times
Abeona plans Jefferies fireside chat, Goldman investor meetings - Stock Titan
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences - Moomoo
ABEOAbeona Therapeutics Inc Stock Price and Quote - Finviz
Lightning eMotors Inc. (ZEV) - Minichart
Abeona Therapeutics director Mark Alvino sells $35,462 in stock By Investing.com - Investing.com India
Insider Sell: Mark Alvino Sells 6,500 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics director Mark Alvino sells $35,462 in stock - Investing.com UK
Abeona Therapeutics (ABEO) director sells 6,500 shares in open-market trade - Stock Titan
May 2026's Top Insider-Owned Growth Companies - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Abeona Therapeutics (NASDAQ: ABEO) Reports $8.7 Million in Q1 Revenue as ZEVASKYN Adoption Accelerates - foreignpolicyjournal.com
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum - TipRanks
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
(ABEO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ABEO: Three Patients Treated in 1Q26 with Two Additional QTCs Activated - Zacks Small Cap Research
Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips - Investing.com
Abeona Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Abeona Therapeutics Q1 2026 earnings preview - MSN
Abeona (ABEO) director 10b5-1 open-market sale of 26,143 shares - Stock Titan
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Malley Brendan M. | SVP, Chief Legal Officer |
Jun 08 '26 |
Sale |
5.43 |
4,826 |
26,203 |
446,308 |
| Vazzano Joseph Walter | Chief Financial Officer |
Jun 09 '26 |
Sale |
5.36 |
39,067 |
209,476 |
518,437 |
| Vazzano Joseph Walter | Chief Financial Officer |
Jun 08 '26 |
Sale |
5.43 |
10,271 |
55,766 |
557,504 |
| Vasanthavada Madhav | Chief Commercial Officer |
Jun 09 '26 |
Sale |
5.30 |
5,450 |
28,908 |
303,451 |
| Vasanthavada Madhav | Chief Commercial Officer |
Jun 08 '26 |
Sale |
5.43 |
4,170 |
22,641 |
308,901 |
| Seshadri Vishwas | Chief Executive Officer |
Jun 09 '26 |
Sale |
5.30 |
31,916 |
169,289 |
1,374,079 |
| Seshadri Vishwas | Chief Executive Officer |
Jun 08 '26 |
Sale |
5.43 |
24,428 |
132,632 |
1,405,995 |
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):